These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33418504)

  • 1. How to select cancer patients for immunotherapy.
    Pfeiffer P; Qvortrup C; Hansen KH
    EBioMedicine; 2021 Jan; 63():103184. PubMed ID: 33418504
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.
    Raibagkar P
    Immunol Lett; 2020 May; 221():72-74. PubMed ID: 32092358
    [No Abstract]   [Full Text] [Related]  

  • 3. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
    Zou Y; Hu X; Zheng S; Yang A; Li X; Tang H; Kong Y; Xie X
    EBioMedicine; 2021 Jan; 63():103137. PubMed ID: 33310681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
    Xu Y; Fu Y; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():2023. PubMed ID: 33123120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.
    Galluzzi L; Humeau J; Buqué A; Zitvogel L; Kroemer G
    Nat Rev Clin Oncol; 2020 Dec; 17(12):725-741. PubMed ID: 32760014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models.
    Agur Z; Elishmereni M; Foryś U; Kogan Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):515-527. PubMed ID: 32535891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-gene signature: a new tool for patient selection for checkpoint inhibitors?
    Sobhani N; Corona SP; Roviello G; Bagby S; D'Angelo A; Iezzi G; Generali D
    Future Oncol; 2020 Jul; 16(19):1327-1330. PubMed ID: 32396404
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.
    Zhang PF; Xie D; Li Q
    Future Oncol; 2020 Jun; 16(17):1189-1198. PubMed ID: 32407173
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.
    Duchemann B; Pluvy J; Crestani B; Zalcman G; Nunes H
    Eur J Cancer; 2021 Mar; 145():179-182. PubMed ID: 33486441
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
    Barroso-Sousa R; Tolaney SM
    Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors - The Need for Innovation.
    Johnson PC; Gainor JF; Sullivan RJ; Longo DL; Chabner B
    N Engl J Med; 2023 Apr; 388(16):1529-1532. PubMed ID: 37075146
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
    Saxena P; Singh PK; Malik PS; Singh N
    Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S; Li X; Nong J; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].
    Reich M; Coutzac C
    Bull Cancer; 2021 Mar; 108(3):228-229. PubMed ID: 33531154
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
    Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
    Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
    Fazio N; Abdel-Rahman O
    Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
    Fernandes S; Varlamov EV; McCartney S; Fleseriu M
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis.
    Li J; Gu J
    Future Oncol; 2019 Nov; 15(31):3633-3646. PubMed ID: 31650854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.